Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS.
Kristin KostkaTalita Duarte SallesAlbert Prats-UribeAnthony G SenaAndrea PistilloSara KhalidLana Y H LaiAsieh GolozarThamir M AlshammariDalia M DawoudFredrik NybergAdam B WilcoxAlan AndrycAndrew WilliamsAnna OstropoletsCarlos AreiaChi Young JungChristopher A HarleChristian G ReichClair BlacketerDaniel R MoralesDavid A DorrEdward BurnElena RoelEng Hooi TanEvan MintyFrank DeFalcoGabriel de MaeztuGigi LiporiHiba AlghoulHong ZhuJason A ThomasJiang BianJimyung ParkJordi Martínez RoldánJose D PosadaJuan M BandaJuan Pablo HorcajadaJulianna KohlerKarishma ShahKarthik NatarajanKristine E LynchLi LiuLisa M SchillingMartina RecaldeMatthew SpotnitzMengchun GongMichael E MathenyNeus ValvenyNicole G WeiskopfNigam ShahOsaid AlserPaula CasajustRae Woong ParkRobert SchuffSarah SeagerScott L DuvallSeng Chan YouSeok-Young SongSergio Fernández-BertolínStephen FortinTanja MagocThomas FalconerVignesh SubbianVojtech HuserWaheed-Ul-Rahman AhmedWilliam CarterYin GuanYankuic GalvanXing HePeter R RijnbeekGeorge HripcsakPatrick B RyanMarc A SuchardDaniel Prieto AlhambraPublished in: Clinical epidemiology (2022)
We constructed a global, multi-centre view to describe trends in COVID-19 progression, management and evolution over time. By characterising baseline variability in patients and geography, our work provides critical context that may otherwise be misconstrued as data quality issues. This is important as we perform studies on adverse events of special interest in COVID-19 vaccine surveillance.